secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProMIS Neurosciences Inc. (PMN)
CIK:        0001374339
Form:       8-K
Filed at:   2025-09-03T23:59:59+00:00
Accession:  0001558370-25-011845
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProMIS Neurosciences advances PMN310 to final dose cohort in Alzheimer's Phase 1b trial
--------------------------------------------------------------------------------

- DSMB unanimously recommends proceeding to third and final dose escalation cohort (20 mg/kg) after safety review.
- Cohort 2 fully enrolled; no cases of amyloid-related imaging abnormalities (ARIA) observed to date.
- Enrollment of Cohort 3 underway; 6-month interim data expected Q2 2026, final top-line results Q4 2026.
- Trial to enroll 128 patients with comprehensive biomarker panel including pTau217, NfL, GFAP, and synaptic markers.
- PMN310 holds FDA Fast Track designation; CEO to present at H.C. Wainwright conference on Sept 10, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374339/000155837025011845/0001558370-25-011845-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374339/000155837025011845/pmn-20250903x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-011845

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer